ArticleOncotarget2015

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.

Luca Mologni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.